β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in BrafV600E-driven thyroid cancer cells
Authors:
Open Access
- 6 July 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1171816
Abstract
Introduction: BRAFV600E mutations frequently occur in papillary thyroid cancer (PTC). β-catenin, encoded by CTNNB1, is a key downstream component of the canonical Wnt signaling pathway and is often overexpressed in PTC. BRAFV600E-driven PTC tumors rely on Wnt/β-catenin signaling to sustain growth and progression.Methods: In the present study, we investigated the tumorigenicity of thyroid cancer cells derived from BRAFV600E PTC mice following Ctnnb1 ablation (BVE-Ctnnb1null).Results: Remarkably, the tumorigenic potential of BVE-Ctnnb1null tumor cells was lost in nude mice. Global gene expression analysis of BVE-Ctnnb1null tumor cells showed up-regulation of NKG2D receptor activating ligands (H60a, H60b, H60c, Raet1a, Raet1b, Raet1c, Raet1d, Raet1e, and Ulbp1) and down-regulation of inhibitory MHC class I molecules H-2L and H-2K2 in BVE-Ctnnb1null tumor cells. In vitro cytotoxicity assay demonstrated that BVE-Ctnnb1wt tumor cells were resistant to NK cell-mediated cytotoxicity, whereas BVE-Ctnnb1null tumor cells were sensitive to NK cell-mediated killing. Furthermore, the overexpression of any one of these NKG2D ligands in the BVE-Ctnnb1wt cell line resulted in a significant reduction of tumor growth in nude mice. Conclusions: Our results indicate that active β-catenin signaling inhibits NK cell-mediated immune responses against thyroid cancer cells. Targeting the β-catenin signaling pathway may have significant therapeutic benefits for BRAF-mutant thyroid cancer by not only inhibiting tumor growth but also enhancing host immune surveillance.Keywords
Funding Information
- King Abdulaziz City for Science and Technology (13-MED1765-20)
- King Faisal Specialist Hospital and Research Centre
This publication has 38 references indexed in Scilit:
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- The Ly49 Gene Family. A Brief Guide to the Nomenclature, Genetics, and Role in Intracellular InfectionFrontiers in Immunology, 2013
- Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin PhosphorylationPLOS ONE, 2012
- Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signalingOncogene, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- The β-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell ProliferationCancer Research, 2009
- Wnt/β-Catenin Signaling in Development and DiseaseCell, 2006
- The balancing act: Inhibitory Ly49 regulate NKG2D-mediated NK cell functionsSeminars in Immunology, 2006
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005